| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1b interim results example | Phase 1b | — | Subscribe to access the data. | Biologics | Nervous System | ||
Phase 1b interim results example | Phase 1b | — | Subscribe to access the data. | Biologics | Nervous System | ||
Phase 1b interim results example | Phase 1b | — | Subscribe to access the data. | Biologics | Nervous System |
Recent Updates
Recently added Catalysts
ProMIS Neurosciences Inc.$14.25
+0.23 (+1.61%)
D 33Pipeline Score Richly Valued Biotech · Clinical
Market Cap
23.63 M
EPS
-19.41
P/E Ratio
-
Value Trade
377.71 K
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
6.97 M
Operating CF
-12.38 M
Total Assets
67.41 M
Total Liabilities
6.69 M
Equity
60.72 M
D/E Ratio
12,345
3.98 %
Week
1.76 %
1 Month
-32.91 %
3 Month
12.62 %
6 Month
-95.02 %
5 Year
-99.32 %
All Time
Cash Data
Cash Position
63.85 M
Monthly Burn
4.13 M
Runway
13.8 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
101.60 K
52 Week Range
6.27 - 39.75
% held by Insiders
19.27 %
% held by Institutions
-
Enterprise Value
-40.21 M
Total Shares
8.97 M
Short %
11.54 %
Float Shares
7.88 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for ProMIS Neurosciences Inc.
424Total events
3Upcoming
36Tier-1 (high impact)
2017 – 2026Coverage
Upcoming catalysts 3
Event history 421
Q3 2026
◆Interim AnalysisPMN310Trial
Blinded interim analysis of PRECISE-AD safety and biomarker data
Alzheimer's diseasesource ↗
Q3 2026
◆Topline ReadoutPMN310Clinical Data
Topline results anticipated in 2H 2026
Alzheimer's diseasesource ↗
Jun 15, 2026
Jun 4, 2026
Q2 2026
◆Interim AnalysisPMN310Trial
Blinded 6-month interim analysis of PRECISE-AD trial
Alzheimer's diseasesource ↗
Q2 2026
◆Topline ReadoutPMN310Clinical Data
Planned data readout from PRECISE-AD trial
Alzheimer's diseasesource ↗
Mar 20, 2026
◆Poster PresentationPresentation
Poster presentation on alpha-synuclein vaccine for Parkinson's at AD/PD 2026
Parkinson's diseasesource ↗
Feb 11, 2026
◆Oral PresentationPresentation
ProMIS Neurosciences to participate in fireside chat at Guggenheim Emerging Outlook: Biotech Summit 2026
Feb 5, 2026
Drug Pipeline Intelligence
D33
Pipeline Score $1M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.1x
rNPV / MCap Top 42%
Micro Cap (rank 529 of 911)
Percentile RankProMIS Neurosciences Inc. faces pipeline headwinds (33/100), with $70M risk-adjusted pipeline value, led by PMN310 in Healthy Participants (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PMN310 Small molecule | Healthy Participants | Phase 1 | NCT06105528 | 7% | $70M | COMPLETED | 40 | - | - | Jul 31, 2024 | - | Jul 25, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
PMN310 Fast Track | Alzheimer's disease | Phase 1b | 2026-02-05 | The study is powered to provide 95% confidence for detection of ARIA. Read More | ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 Read More | |
PMN310 Fast Track | Alzheimer's disease | Phase 1b | 2026-02-05 | The study is powered to provide 95% confidence for detection of ARIA. Read More | ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 Read More | |
PMN310 Fast Track | Alzheimer's disease | Phase 1b | 2026-02-05 | The study is powered to provide 95% confidence for detection of ARIA. Read More | ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PMN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PMN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PMNProMIS Neurosciences to Participate in Upcoming Conferences in June
ProMIS Neurosciences Inc. will participate in several conferences in June 2026, including the Jefferies Global Healthcare Conference and the Oppenheimer CNS Summit. CEO Neil Warma will present the company's EpiSelect™ platform and its lead Alzheimer's candidate, PMN310. The company expects to report interim data from its Phase 1b trial in early Q3 2026.
Read more →PMNProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
ProMIS Neurosciences reported its Q1 2026 financial results, highlighting a successful PIPE financing of up to $175 million to fund ongoing operations through 2027. The PRECISE-AD Phase 1b clinical trial for PMN310 is fully enrolled, with an interim analysis expected in early Q3 2026. The company aims to provide insights into PMN310's safety and efficacy in treating Alzheimer's disease.
Read more →PMN▼ -9.1%on this news· ran to -26% by day 3
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
ProMIS Neurosciences announced its financial results for 2025, highlighting the completion of enrollment in the PRECISE-AD Phase 1b trial for Alzheimer's disease with 144 patients. The company reported a favorable safety profile for its lead candidate PMN310, which has been granted Fast Track Designation by the FDA. A transformational financing of up to $175 million was closed to support ongoing development efforts.
Read more →PMN▼ -13%on this news
ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)
ProMIS Neurosciences announced that it will present two posters at the AD/PD 2026 conference, showcasing research on therapies targeting misfolded proteins in neurodegenerative diseases. The presentations highlight ongoing work on a vaccine against TDP-43 proteinopathies and an antibody response for toxic alpha-synuclein species. CEO Neil Warma emphasized the importance of this opportunity to advance their candidates' therapeutic approaches for ALS and Parkinson's diseases. The conference will be held in Copenhagen from March 17-21, 2026.
Read more →PMN▼ -16.3%on this news
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
ProMIS Neurosciences will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, featuring a fireside chat and investor meetings. The company is focused on developing therapies for Alzheimer's disease, with its lead candidate PMN310 showing promise in clinical trials. The PRECISE-AD trial aims to evaluate PMN310's safety and efficacy in patients with mild cognitive impairment due to Alzheimer's.
Read more →PMN▲ +18%on this news
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
ProMIS Neurosciences has announced a private placement financing of up to $175 million to support its Phase 1b Alzheimer's disease study and other clinical milestones. The financing is expected to close on February 3, 2026, and will extend the company's cash runway into 2028. The investment is co-led by Janus Henderson and Ally Bridge Group, with participation from various institutional investors.
Read more →PMN▼ -5.6%on this news
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
ProMIS Neurosciences has completed enrollment of 144 patients in its PRECISE-AD Phase 1b clinical trial for PMN310, an antibody aimed at treating Alzheimer's disease. The trial seeks to assess the treatment's safety and efficacy over a 12-month period. With a favorable safety profile and no serious adverse events reported, the company anticipates significant data insights from a blinded interim analysis in Q2 2026 and final results in Q4 2026. Strong enthusiasm from patients and physicians reflects the potential value PMN310 may bring to Alzheimer's therapy.
Read more →PMN▲ +12%on this news
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
ProMIS Neurosciences announced a new publication in a peer-reviewed journal demonstrating that its antibody candidate PMN310 selectively targets toxic oligomers related to Alzheimer's disease. The study indicates that PMN310 may improve clinical outcomes by preserving binding to relevant toxic Aβ species and avoiding off-target binding to non-pathogenic forms. With a potential reduction in amyloid-related imaging abnormalities (ARIA), the ongoing PRECISE-AD trial aims to further evaluate PMN310's efficacy and safety, with preliminary results expected in Q2 2026.
Read more →PMNProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
ProMIS Neurosciences announced a peer-reviewed publication validating plasma pTau as a predictive endpoint in Alzheimer's trials. The analysis indicates that plasma pTau can serve as a primary endpoint in early-stage clinical trials, supporting the ongoing Phase 1b PRECISE-AD trial of PMN310. The company anticipates a Q2 2026 interim readout, which may provide early insights into PMN310's efficacy.
Read more →PMNProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
ProMIS Neurosciences will participate in the 8th Annual Evercore Healthcare Conference, where CEO Neil Warma will engage in a fireside chat and investor meetings. The company is focused on developing therapies for Alzheimer's disease, with its lead candidate PMN310 currently in a Phase 1b clinical trial. PMN310 has received Fast Track designation from the FDA, highlighting its potential in treating Alzheimer's.
Read more →PMN▼ -22.4%on this news· ran to -36% by day 3
ProMIS Neurosciences Announces Reverse Stock Split Cambridge, Mass.
ProMIS Neurosciences Inc. has announced a one-for-twenty-five reverse stock split of its common shares, effective November 28, 2025. The decision aims to address compliance with Nasdaq's minimum bid price requirements after receiving a deficiency notice. The reverse split will reduce the total number of outstanding shares significantly, while adjustments will also be made to equity incentive plans and existing warrants. ProMIS believes that this move could increase its stock price and help maintain its Nasdaq listing.
Read more →PMNProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights
ProMIS Neurosciences reported its third quarter 2025 financial results, highlighting significant progress in its Phase 1b trial for Alzheimer's disease with PMN310. The trial is over 85% enrolled, and PMN310 has shown a favorable safety profile. The company anticipates reporting interim data in Q2 2026 and final results in Q4 2026, reinforcing its commitment to developing therapies for neurodegenerative diseases.
Read more →PMNProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
ProMIS Neurosciences will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference on November 10, 2025. CEO Neil Warma and senior management will engage in a fireside chat and investor meetings. The company is advancing its lead product candidate, PMN310, aimed at treating Alzheimer's disease, which has received Fast Track designation from the FDA.
Read more →PMNProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group
ProMIS Neurosciences has appointed Slanix Paul Alex, Pharm.D., to its Board of Directors, enhancing its strategic vision and investor engagement. Dr. Alex's extensive experience in healthcare investment is expected to provide valuable insights as the company advances its Alzheimer's program, PMN310, with key data readouts planned for 2026. This move reinforces ProMIS's commitment to developing innovative therapies for neurodegenerative diseases.
Read more →PMN▼ -14.8%on this news
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310
ProMIS Neurosciences has received approval from the Data and Safety Monitoring Board (DSMB) to advance to the final dose escalation cohort in its Phase 1b trial for PMN310, a treatment for Alzheimer's disease. Cohort 2 is fully enrolled, and no amyloid-related imaging abnormalities have been observed. The trial aims to enroll 128 patients and is set to report interim data in Q2 2026 and final results in Q4 2026.
Read more →PMNProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights U.S. FDA Grants Fast Track Designation for PMN310 in Alzheimer's Disease, enhancing program's potential for priority review PREC
ProMIS Neurosciences has announced its financial results for Q2 2025 along with significant milestones, including receiving Fast Track designation from the U.S. FDA for its Alzheimer's treatment PMN310. The ongoing PRECISE-AD Phase 1b trial is over 50% enrolled, reporting no adverse events such as amyloid-related imaging abnormalities. The company raised $21.6 million in funding in July 2025 to further advance PMN310's development, with expected interim results in mid-2026 and final results by late 2026.
Read more →PMN▼ -6.7%on this news
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
ProMIS Neurosciences will present its protein-misfolding drug discovery platform and the PRECISE-AD trial design at the 2025 Alzheimer's Association International Conference. The PRECISE-AD trial is a Phase 1b study evaluating PMN310, a novel therapeutic candidate for Alzheimer's disease, which has shown promising enrollment rates and received FDA Fast Track designation. The trial aims to assess the safety and efficacy of PMN310 while minimizing risks associated with other therapies.
Read more →PMN▼ -8.8%on this news· ran to -22% by day 3shared move
ProMIS Neurosciences Announces Private Placement Financing
ProMIS Neurosciences has announced a private placement financing agreement to raise approximately $3.0 million through the sale of warrants. The financing is expected to close on July 29, 2025, and proceeds will be used to advance the clinical development of PMN310 and for general corporate expenses. The company anticipates total gross proceeds of about $12.0 million, including existing warrants.
Read more →PMNProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the- Market Under Nasdaq Rules CAMBRIDGE, Massachusetts., July 22 , 2025 - ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biote
ProMIS Neurosciences announced a registered direct offering that will raise $0.8 million from an institutional investor to support its therapeutic development. The financing is targeted towards advancing PMN310, its leading candidate aimed at treating neurodegenerative diseases. The Pre-Funded Warrants for 984,736 common shares were priced at $0.8124 each and are set to close around July 24, 2025, subject to customary conditions. This move reflects ProMIS's strategy to leverage market conditions for funding key projects in its pipeline.
Read more →PMN▼ -26.8%on this newsshared move
ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules
ProMIS Neurosciences has announced a registered direct offering, raising $0.8 million from an institutional investor. The funds will be used to advance the clinical development of PMN310, its lead therapeutic candidate targeting neurodegenerative diseases. The offering is expected to close around July 24, 2025, subject to customary conditions.
Read more →PMN▲ +154.5%on this newsshared move
ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease
ProMIS Neurosciences has received Fast Track designation from the FDA for PMN310, its lead candidate for treating Alzheimer's disease. This designation aims to expedite the development of therapies addressing significant medical needs. The ongoing PRECISE-AD Phase 1b trial will evaluate PMN310's safety and efficacy, with interim results expected in mid-2026.
Read more →PMNProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
ProMIS Neurosciences announced its participation in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, where CEO Neil Warma will present. The company is focused on developing therapeutic antibodies, specifically PMN310, aimed at treating Alzheimer's Disease and other neurodegenerative conditions. ProMIS has recently initiated the PRECISE-AD trial to evaluate PMN310's safety and efficacy compared to traditional therapies. This trial represents a significant step in monitoring biomarkers associated with Alzheimer's pathology.
Read more →PMNProMIS Neurosciences Announces First Quarter 2025 Financial Results First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer's Disease Six Month Interim Results Expected in 1H 2026 Topline Results Antici
ProMIS Neurosciences announced that it has completed the first cohort in its PRECISE-AD trial testing PMN310, an antibody candidate for Alzheimer's disease. The company reported financial results for Q1 2025, highlighting rapid enrollment for the trial, which suggests strong enthusiasm from the research community. Interim results are anticipated in the first half of 2026, with topline results expected by the end of that year. While the progress is promising, the company faces potential financial challenges as evidenced by decreased cash reserves.
Read more →PMNProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheime
ProMIS Neurosciences has reported its financial results for the fiscal year 2024, highlighting a significant milestone with the initiation of its Phase 1b clinical trial for PMN310, an antibody candidate for Alzheimer's disease. The company has successfully begun dosing patients and is optimistic about future data, with interim results expected in 2026. Additionally, ProMIS has expanded its intellectual property portfolio significantly over the past year and remains actively engaged in developing therapies for other neurodegenerative diseases.
Read more →PMNProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference
ProMIS Neurosciences Inc. announced its plans to present preclinical data at the 2025 Alzheimer's and Parkinson's Disease International Conference in Vienna. The company aims to showcase advancements from its computational modeling platform in the development of antibodies and vaccines targeting toxic misfolded proteins. Highlighted studies include successful immunization strategies against amyloid-beta and alpha-synuclein, which could offer new treatment avenues for neurodegenerative diseases. The results point to a novel approach in targeting specific misfolded proteins, potentially enhancing therapeutic effectiveness.
Read more →PMNProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting
ProMIS Neurosciences Inc. announced that it will present preclinical data on computationally-derived vaccines targeting neurodegenerative diseases at the upcoming American Academy of Neurology Annual Meeting in April 2025. The data suggest potential breakthroughs in vaccine design for conditions like Alzheimer's disease and multiple system atrophy. Notably, the company's lead product, PMN310, has shown the ability to selectively bind and target toxic oligomers associated with these diseases. This innovative approach could address significant challenges in developing effective treatments for neurodegenerative conditions.
Read more →PMNProMIS Neurosciences to Participate in the 37th Annual Roth Conference
ProMIS Neurosciences, a clinical-stage biotechnology firm, will participate in the 37th Annual Roth Conference where CEO Neil Warma is set to engage in a fireside chat. This event will take place on March 18, 2025, focusing on the company’s advancements in antibody therapeutics targeting neurodegenerative diseases. Notably, ProMIS is progressing with PMN310, its lead candidate for Alzheimer's disease, currently in Phase 1b clinical trials. The fireside chat will be accessible via live webcast for interested parties, highlighting the company's initiatives.
Read more →PMN▼ -6.2%on this news
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease Rapid Enrollment and Dosing of First Patients Encouraging and Underscores Unmet Need for Better Treatment Options f
ProMIS Neurosciences has initiated dosing in its Phase 1b PRECISE-AD trial for PMN310, a monoclonal antibody targeting Alzheimer's disease. This trial seeks to assess the safety, tolerability, and pharmacokinetics of PMN310 while addressing an urgent need for effective therapies in Alzheimer's treatment. Interim results are anticipated in the first half of 2026, with topline results expected later in the year. PMN310's unique mechanism aims to target toxic oligomers, potentially offering a new path for treatment in Alzheimer's patients.
Read more →PMNProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference
ProMIS Neurosciences, Inc. will have its CEO Neil Warma participate in the Guggenheim Securities SMID Cap Biotech Conference on February 5, 2025. The company's focus is on developing antibody therapeutics targeting misfolded proteins in neurodegenerative diseases, specifically its lead candidate PMN310 for Alzheimer's disease. The event will be accessible via a live webcast for interested stakeholders, highlighting the company's outreach efforts towards investors and the public.
Read more →PMNNASDAQ: PMN Targeting the underlying cause of neurodegenerative diseases Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential Legal Disclaimers This slide deck may contain certain forward-looking information. Su
ProMIS Neurosciences, Inc. (NASDAQ: PMN) is targeting neurodegenerative diseases through a robust pipeline of antibody and vaccine candidates. Notably, clinical candidate PMN310 has shown positive early results in a Phase 1a study, demonstrating tolerability and the potential to cross the blood-brain barrier. The company is committed to exploring treatments for Alzheimer's disease, ALS, and other conditions using its innovative platform. Strategic milestones are anticipated in the coming years to advance their research and development efforts.
Read more →PMNProMIS Neurosciences Issues Letter to Shareholders
ProMIS Neurosciences Inc. has updated shareholders on its progress for 2025, highlighting significant advancements in developing PMN310, a treatment for Alzheimer's disease. The CEO expressed optimism following the completion of the Phase 1a clinical trial, reporting positive results and emphasizing the potential of PMN310 to uniquely target toxic oligomers. Additionally, the company has secured $122.7 million in financing for ongoing trials, aiming to reshape treatment for neurodegenerative diseases. ProMIS also outlined plans to enhance its pipeline with further drug candidates aimed at related conditions.
Read more →PMNProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer's Disease Targeting toxic oligomers without binding to plaque, designed to reduce the risk of ARIA and potentially deliver enhanced outcome
ProMIS Neurosciences has launched its Phase 1b clinical trial, PRECISE-AD, for PMN310, aimed at treating Alzheimer's disease. This monoclonal antibody targets toxic amyloid-beta oligomers while avoiding plaque, potentially reducing the risk of amyloid-related imaging abnormalities (ARIA). The trial will assess safety and efficacy in about 100 patients with mild cognitive impairment or early Alzheimer's. Results from prior studies indicate promising safety and tolerability for PMN310, with more data anticipated in the future.
Read more →PMNProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference
ProMIS Neurosciences Inc. will participate in the 7th Annual Evercore HealthCONx Conference on December 3, 2024. CEO Neil Warma is scheduled for a fireside chat during the conference in Coral Gables, Florida. The company's lead product candidate, PMN310, has completed a Phase 1a study and is expected to begin a Phase 1b trial by the end of 2024. ProMIS focuses on therapeutics targeting toxic misfolded proteins in neurodegenerative diseases.
Read more →PMNProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly
ProMIS Neurosciences announced its third quarter 2024 financial results, highlighting positive findings from its Phase 1a clinical trial for PMN310, an antibody targeting toxic misfolded proteins in Alzheimer's disease. The trial showed that PMN310 was generally well-tolerated and exhibited cerebrospinal fluid levels indicative of potential target engagement. The company plans to commence a Phase 1b trial in patients with Alzheimer's by the end of 2024. Additionally, ProMIS secured equity financing, which could provide up to $122.7 million to further develop its pipeline of candidates.
Read more →PMNProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
ProMIS Neurosciences Inc. announced that CEO Neil Warma will participate in Guggenheim’s Inaugural Healthcare Innovation Conference on November 13, 2024. The event will feature a fireside chat and highlights ProMIS's commitment to addressing neurodegenerative diseases through their innovative research. The company is known for its development of antibody therapeutics, with PMN310 as a key product candidate aimed at Alzheimer's disease, having completed a Phase 1a clinical study.
Read more →PMN▲ +5.8%on this news· ran to +23% by day 1
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
ProMIS Neurosciences presented positive data from the Phase 1a clinical trial of PMN310 at the 17th Clinical Trials on Alzheimer’s Disease Conference. The trial indicated that PMN310 was well-tolerated and showed the ability to cross the blood-brain barrier, suggesting its potential efficacy in Alzheimer's disease. ProMIS plans to initiate a Phase 1b clinical trial targeting patients with mild cognitive impairment due to Alzheimer's by the end of 2024, reinforcing its commitment to advancing the treatment for this neurodegenerative condition.
Read more →PMNProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
ProMIS Neurosciences Inc. announced that it will present preclinical data on its leading candidate PMN310 at the 4th International Conference on Cognitive & Behavioral Neurosciences. The data emphasize PMN310's ability to selectively target toxic amyloid-beta oligomers, potentially leading to greater efficacy as a treatment for Alzheimer's disease. Additionally, PMN310's design limits interactions with amyloid plaques, reducing the risk of amyloid-related imaging abnormalities. This presentation could strengthen the outlook for PMN310, especially following positive outcomes from prior clinical trials.
Read more →PMNProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
ProMIS Neurosciences Inc. announced that its CEO, Neil Warma, will present at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will focus on the company's innovative antibody therapeutics aimed at targeting toxic misfolded proteins in diseases such as Alzheimer's and ALS. Additionally, Mr. Warma will be available for virtual one-on-one meetings with investors during the conference, which takes place from September 9-10, 2024. The recorded presentation will also be accessible for one month post-event on the company's website.
Read more →PMN▼ -11.5%on this news
ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights Reported positive topline data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer's disease that
ProMIS Neurosciences announced its financial results for Q2 2024, highlighting positive topline data from the Phase 1a clinical trial of PMN310 for Alzheimer's disease. The trial met objectives for safety and tolerability, leading to significant financing of up to $122.7 million to advance to Phase 1b. PMN310 is designed to target toxic amyloid-beta oligomers, which may mitigate serious side effects common in existing treatments. The upcoming Phase 1b trial aims to enroll 100 patients and assess critical endpoints over a 12-month period.
Read more →PMN▲ +18.3%on this newsshared move
ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology
ProMIS Neurosciences has published two important papers elucidating the pathogenic role of misfolded SOD1 aggregates in ALS. The research demonstrates that these aggregates are present in various forms of the disease, reinforcing their potential as therapeutic targets and biomarkers. Additionally, the studies highlight previously unrecognized regions of SOD1 that may play a critical role in the aggregation process, signaling new avenues for ALS treatment development.
Read more →PMNProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
ProMIS Neurosciences Inc. announced its participation in the BTIG Virtual Biotechnology Conference scheduled for August 6, 2024. The company's interim CEO Neil Warma and Chief Medical Officer Larry Altstiel will engage in a fireside chat during the event to discuss their advancements in therapeutics targeting neurodegenerative diseases. ProMIS focuses on developing treatments for conditions like Alzheimer's disease, ALS, and multiple system atrophy through innovative methods.
Read more →PMN▼ -17.4%on this newsshared move
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
ProMIS Neurosciences Inc. presented promising preclinical data on its novel vaccine approach for Alzheimer's disease at the 2024 Alzheimer’s Association International Conference. The data demonstrated strong antibody responses with no pro-inflammatory T cell responses, supporting the targeting of toxic amyloid-beta oligomers. The findings suggest that their vaccine candidates might be effective in preventing Alzheimer’s disease in at-risk individuals and in treating diagnosed patients to slow disease progression. The research indicates a significant step forward in Alzheimer's vaccine development.
Read more →PMN▼ -20.7%on this newsshared move
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
ProMIS Neurosciences has reported positive top-line data from its Phase 1a clinical trial of PMN310, an antibody therapeutic for Alzheimer's disease. Results indicate a good safety profile and tolerability among healthy volunteers, with promising pharmacokinetics suggesting the antibody effectively targets soluble amyloid-beta oligomers. The company is set to proceed with the Phase 1b clinical trial in Alzheimer's patients in the latter half of 2024, following encouraging findings from the initial cohorts.
Read more →PMN▼ -20.7%on this newsshared move
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing $30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with certain of the warrants subject to
ProMIS Neurosciences announced a private placement financing deal totaling up to $122.7 million to support the development of its Alzheimer's antibody PMN310. This includes an upfront financing of $30.3 million and an additional $92.4 million based on warrant exercises subject to shareholder approval. Participation was noted from various institutional investors, enhancing the company's financial standing. Proceeds are expected to further advancements in clinical trials and other general expenses.
Read more →PMN▼ -20.7%on this newsshared move
ProMIS Neurosciences Reports Promising Top-Line Data from its Phase 1a Alzheimer s Trial Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers an
ProMIS Neurosciences announced positive top-line results from its Phase 1a clinical trial of PMN310, showing a favorable safety profile and tolerability in healthy volunteers. The trial indicated dose-dependent levels of the PMN310 antibody in cerebrospinal fluid (CSF), suggesting its potential effectiveness in targeting Alzheimer's disease. ProMIS plans to advance into a Phase 1b trial in Alzheimer's patients in the second half of 2024, which is supported by the drug's ability to cross the blood-brain barrier. The encouraging safety data positions PMN310 as a promising candidate for addressing neurodegenerative diseases.
Read more →PMNProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer's disease on track for mid-2024 C
ProMIS Neurosciences reported its financial results for Q1 2024 and highlighted progress in its clinical trials. The company anticipates top-line data from its first-in-human Phase 1a trial of PMN310 for Alzheimer's disease by mid-2024. Positive results could lead to a Phase 1b study later in the year. However, financial constraints and significant accumulated losses pose risks to the advancement of its clinical programs.
Read more →PMNProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies Study results support differentiation of PMN310 from other amyloid-beta-directed antibodies CAMBRIDGE
ProMIS Neurosciences has published a study demonstrating PMN310's superior selectivity for toxic soluble oligomers of amyloid-beta compared to other antibodies. This selectivity may contribute to improved clinical outcomes and reduced risks of amyloid-related imaging abnormalities (ARIA). PMN310 is currently undergoing Phase 1a clinical trials, with results expected in mid-2024 before advancing to further studies.
Read more →PMNProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
ProMIS Neurosciences Inc. has published supportive preclinical data in the Journal of Biological Chemistry regarding the interaction of toxic proteins TDP-43 and SOD1, highlighting their role in ALS. The study provides evidence that misfolded TDP-43 leads to SOD1 aggregation, damaging motor neurons in zebrafish models. ProMIS's therapeutic candidate PMN267 targets this specific interaction, demonstrating promise as a potential ALS treatment. The publication underscores the significance of understanding misfolded protein interactions in neurodegenerative diseases.
Read more →PMNProMIS Neurosciences to Present in Upcoming Investor Conferences in April
ProMIS Neurosciences Inc. announced its participation in three upcoming investor conferences in April 2024. CEO Neil Warma will present corporate overviews at the LD Micro Invitational XIV, the Needham Virtual Healthcare Conference, and the Bloom Burton & Co. Healthcare Investor Conference. These presentations aim to enhance investor awareness and highlight the company's unique approach to developing therapeutics targeting toxic misfolded proteins related to neurodegenerative diseases. The events are open to live webcasts, providing broader access to interested stakeholders.
Read more →PMN▲ +7.3%on this news· ran to +18% by day 1shared move
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights Top-line Data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer's disease on track for mid-2024 CAMBR
ProMIS Neurosciences announced its full-year financial results for 2023, highlighting its progress in transitioning to a clinical development company. The company is nearing the completion of its Phase 1a trial for its lead candidate, PMN310, aimed at treating Alzheimer's disease, with top-line data expected by mid-2024. Interim CEO Neil Warma expressed confidence in the potential for PMN310 to positively impact Alzheimer's patients and the company's plans to advance into further clinical stages.
Read more →PMNProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
ProMIS Neurosciences announced significant advancements in its global intellectual property portfolio, securing multiple allowed patent applications for its lead product candidate, PMN310, designed to treat Alzheimer’s disease. Recent approvals include patents granted by the European Patent Office, the Japanese Patent Office, and IP Australia, as well as a US patent related to immunogenic compositions. This expansion brings the total to ten patents for PMN310, reinforcing the company's innovative strategy to combat neurodegenerative diseases. The CEO emphasized the strong market potential and the importance of these protections in securing their unique therapeutic approach.
Read more →PMN▼ -10.1%on this news
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
ProMIS Neurosciences Inc. will present at the 2024 BIO CEO & Investor Conference in New York on February 27, 2024. CEO Neil Warma will lead the presentation, which highlights the company's efforts in developing therapeutics for neurodegenerative diseases. Additionally, ProMIS management will hold one-on-one meetings during the event. The company utilizes a specialized target discovery engine to create antibody therapeutics for diseases such as Alzheimer's, ALS, and MSA.
Read more →PMN▲ +7.2%on this news
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
ProMIS Neurosciences Inc. has selected PMN400 as its lead vaccine candidate for treating various synucleinopathies, including Parkinson's disease and Multiple System Atrophy. The selection stems from a research grant of $1.16 million from the Weston Family Foundation, which aims to enhance the company's capabilities in developing targeted antibody therapeutics and vaccines. The vaccine has shown promise in preliminary studies and results are set to be presented at the upcoming American Academy of Neurology meeting in April 2024. This development signifies a key milestone in the company's focus on neurodegenerative diseases.
Read more →PMN▼ -7.8%on this newsshared move
ProMIS Neurosciences, Inc. Announces Leadership Transition Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim Chief Executive Officer CAMBRIDGE, Massachusetts and
ProMIS Neurosciences, Inc. announced a leadership transition as Neil Warma was appointed interim CEO following Gail Farfel's departure. Warma's extensive background in the biotechnology industry is expected to pave the way for continued progress in advancing the clinical program for PMN310, targeting Alzheimer's disease. The company emphasizes strategic partnerships and innovative approaches in drug development to target misfolded proteins associated with neurodegenerative diseases. The transition aims to reinforce the company's commitment to transforming treatments in this field.
Read more →PMNProMIS Neurosciences Announces Publication on Novel Target for ALS
ProMIS Neurosciences has published a study in Acta Neuropathologica Communications, identifying RACK1 as a novel target for treating Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Degeneration (FTLD). The study presents evidence that RACK1 co-aggregates with pathological proteins TDP-43 and FUS, inhibiting protein synthesis. By knocking down RACK1, the research suggests potential restoration of protein synthesis and alleviation of neurodegeneration in animal models. This publication is expected to drive forward the company's clinical initiatives, particularly with its lead product PMN310 for Alzheimer's disease.
Read more →PMN▲ +6.7%on this news
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease Advances novel monoclonal antibody designed to be highly selective for toxic oligomers of amyloid-beta (A ) in f
ProMIS Neurosciences has begun dosing subjects in its Phase 1a clinical trial of PMN310, a monoclonal antibody aimed at treating Alzheimer's disease. This trial marks a significant milestone for the company as it transitions into a clinical stage entity. PMN310 targets toxic oligomers of amyloid-beta, which are linked to Alzheimer's pathology. The trial will involve healthy volunteers and aims to evaluate the safety and pharmacokinetics of the treatment, with initial results expected in the first half of 2024.
Read more →PMN▼ -12.2%on this news
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights Raised $20.4 million in PIPE gross proceeds to support continued development of Company's PMN310 and novel antibody therapeutics t
ProMIS Neurosciences has reported its third quarter 2023 financial results, highlighting the $20.4 million raised through a PIPE financing. The company is set to begin dosing subjects in a Phase 1a clinical trial for PMN310, aimed at treating Alzheimer's disease. With promising nonclinical data supporting PMN310's specificity for toxic amyloid-beta oligomers, ProMIS is optimistic about its therapeutic potential. Additionally, the company continues to advance its antibody-based programs for neurodegenerative diseases.
Read more →PMNProMIS Neurosciences Closes $20.4 Million Private Placement Financing
ProMIS Neurosciences Inc. has completed a private placement financing, raising approximately $20.4 million through the sale of common share units and pre-funded units. These funds are earmarked for advancing their lead therapeutic candidate, PMN310, alongside supporting working capital and corporate expenses. The offering was facilitated by BTIG, LLC as the placement agent and is noted to be a private investment not registered under the Securities Act of 1933. ProMIS focuses on developing antibody therapeutics targeting toxic misfolded proteins associated with neurodegenerative diseases.
Read more →PMNProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
ProMIS Neurosciences Inc. has announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference, scheduled for September 12, 2023. CEO Gail Farfel and CMO Larry Altstiel will present on the company's innovative approach to developing antibody therapeutics targeted at toxic misfolded proteins in neurodegenerative diseases. The event highlights the company's commitment to addressing serious conditions such as Alzheimer's disease, ALS, and multiple system atrophy. A live webcast of their presentation will be available for at least 30 days afterward.
Read more →PMN▼ -9.1%on this news
ProMIS Neurosciences Announces $20.4 Million Private Placement Financing At-the-Market Fundraise supports Company through several potentially value-creating milestones and beyond TORONTO, Ontario and
ProMIS Neurosciences Inc. has announced a private placement financing generating approximately $20.4 million through the sale of common and pre-funded units. This funding is aimed at advancing the clinical development of their lead therapeutic candidate, PMN310, and for general corporate purposes. Notably, insiders are also subscribing for a portion of the offering, which will be classified as a related party transaction. The transaction is set to close on August 23, 2023, pending customary conditions.
Read more →PMNProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights Presented compelling preclinical data supporting therapeutic potential of PMN310 to treat Alzheimer's disease, and the promise of
ProMIS Neurosciences released its financial results for Q2 2023, showcasing preclinical data for PMN310 suggesting its therapeutic potential for Alzheimer's disease. The data presented at AAIC 2023 emphasizes PMN310's selectivity for toxic amyloid beta oligomers, which could lead to improved safety and effectiveness. With FDA clearance for a Phase 1a study, the company is poised to advance its research further. However, the company faces financial strains, including a significant accumulated deficit and a current liability exceeding its assets.
Read more →PMN▲ +120.3%on this news
ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline
ProMIS Neurosciences Inc. presented promising preclinical data on its lead Alzheimer’s treatment candidate, PMN310, showing it selectively targets toxic amyloid-beta oligomers. The company also discussed a novel vaccine candidate designed to elicit a strong immune response against these harmful proteins. Both candidates utilized a proprietary computational modeling platform, enhancing their specificity. ProMIS has begun preparations for clinical trials after receiving FDA clearance for PMN310, which aims to evaluate its pharmacokinetics and safety in healthy volunteers.
Read more →PMNProMIS Announces Completion of Continuance
ProMIS Neurosciences Inc. has announced the successful completion of its continuance from the Canada Business Corporations Act to the Business Corporations Act in Ontario, effective July 13, 2023. This transition was overwhelmingly approved by shareholders during the Annual Meeting held on June 29, 2023. The company aims to enhance management functions through this continuance, and it does not anticipate any impact on its current operations or structure. ProMIS continues its focus on developing therapeutic antibodies for neurodegenerative diseases from its labs in British Columbia and its office in Cambridge, Massachusetts.
Read more →PMN▼ -8.1%on this news· ran to -27% by day 3
ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange Company to voluntarily delist from the Toronto Stock Exchange (TSX) Last trading day on TSX will be
ProMIS Neurosciences Inc. plans to consolidate trading on the Nasdaq Exchange and will delist its common shares from the Toronto Stock Exchange (TSX) effective July 21, 2023. The company aims to simplify trading operations and improve liquidity by focusing on its Nasdaq listing, which has become its primary market. Shareholders in Canadian brokerage accounts will still have access to trade shares listed on Nasdaq. The delisting does not require shareholder approval as Nasdaq is an acceptable alternative market.
Read more →PMNProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved
ProMIS Neurosciences Inc. held its Annual Meeting of Shareholders on June 29, 2023, where all proposed resolutions were approved by a significant majority. Shareholders re-elected seven directors, including CEO Dr. Gail Farfel, and appointed Baker Tilly US, LLP as the new auditor. Additionally, shareholders authorized the Company to continue under the Business Corporations Act in Ontario. The meeting was attended by a representative proportion of common and preferred shares, indicating strong investor engagement.
Read more →PMNProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights Received FDA clearance for investigational new drug (IND) application for lead therapeutic candidate, PMN310, in Alzheimer's disea
ProMIS Neurosciences Inc. announced its first quarter 2023 financial results, revealing significant milestones, including FDA clearance for its investigational new drug application for PMN310, targeted at Alzheimer's disease. The company reported a net loss of approximately $4.96 million for the quarter and showed concerns over liquidity as current liabilities exceed current assets. Additionally, ProMIS presented data supporting its amyloid-beta vaccine candidate and new ALS treatment targets at recent neurology conferences. The biotechnology firm continues to advance its therapeutic programs throughout 2023.
Read more →PMNProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer's Disease In preclinical studies, PMN310 demonstrated the ability to selectively target and protect again
ProMIS Neurosciences has received FDA clearance for its Investigational New Drug application for PMN310, an antibody aimed at treating Alzheimer's Disease. This new therapy targets toxic oligomers of amyloid-beta, showing greater selective binding compared to existing treatments. The company plans to initiate a Phase 1a clinical trial to evaluate the pharmacokinetics and safety of PMN310 in healthy volunteers. ProMIS believes the unique targeting mechanism may reduce the risk of side effects seen with other therapies.
Read more →PMN▲ +8.3%on this news· ran to +39% by day 3
ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meeting
ProMIS Neurosciences Inc. announced positive preclinical data for its lead candidate PMN310 in Alzheimer's disease, highlighting its selective binding to toxic amyloid-beta oligomers. The company also presented data supporting the potential of misfolded RACK1 as a target for ALS and FTLD-TDP at the American Academy of Neurology Annual Meeting. PMN310's unique binding characteristics could provide greater therapeutic potential while minimizing side effects associated with other therapies. Both sets of data emphasize ProMIS's focus on innovative solutions for neurodegenerative disorders.
Read more →PMNProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310 TORONTO, Ontario and
ProMIS Neurosciences has submitted an Investigational New Drug (IND) application to the FDA for its lead antibody PMN310, aimed at treating Alzheimer's disease. This submission marks a crucial step for the company as it seeks to progress its innovative therapeutic candidate into clinical studies. PMN310 has shown promising results in preclinical evaluations, particularly in targeting toxic oligomers thought to drive Alzheimer's pathology. The management expresses optimism about the potential of PMN310, which could offer a differentiated treatment profile compared to existing therapies.
Read more →PMN▲ +6%on this news
ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting
ProMIS Neurosciences Inc. has announced that it will present at the American Academy of Neurology 2023 Annual Meeting in Boston, MA. The presentations will focus on the company's advancements in antibody therapeutics for neurodegenerative diseases, including Alzheimer's disease, ALS, and multiple system atrophy. Notable topics include the lead drug candidate PMN310 and preliminary research on an Alzheimer's vaccine. This event marks a significant opportunity for ProMIS to share critical insights and data within the neurology community.
Read more →PMN▲ +6%on this news
ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023
ProMIS Neurosciences Inc. plans to present new preclinical data for its lead Alzheimer’s candidate, PMN310, at the AD/PD 2023 conference. The presentation will discuss how PMN310 differentiates itself from other amyloid-beta-directed antibodies by selectively targeting toxic brain oligomers. This data may potentially contribute to enhancements in therapy for neurodegenerative diseases, particularly Alzheimer’s disease.
Read more →PMN▼ -5.4%on this newsshared move
Promis Neurosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference
ProMIS Neurosciences Inc. announced that CEO Gail Farfel will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023. The biotechnology company focuses on developing antibody therapeutics for neurodegenerative diseases, including Alzheimer's disease, ALS, and MSA. The presentation will be webcasted and available on the company's website for a month following the event. ProMIS continues to innovate with its unique target discovery platform.
Read more →PMN▼ -5.4%on this newsshared move
ProMIS Neurosciences Announces Full Year 2022 Financial Results and Recent Highlights - Completed all preclinical studies and manufacturing to support PMN310 IND submission to U.S. Food and Drug Administration - Preclini
ProMIS Neurosciences Inc. reported its full year 2022 financial results showcasing a net loss and an overall decline in current assets. However, the company is advancing its lead Alzheimer's product candidate, PMN310, with plans to file an IND application within the next 60 days. ProMIS is also working on two other discovery programs and aims to provide updates on its progress soon. The current focus is on clinical advancements and responding to the needs of patients with limited treatment options for neurodegenerative diseases.
Read more →PMNProMIS Neurosciences Announces Third Quarter 2022 Financial Results and Recent Highlights - Closed US$7.4 million private placement - Appointed Gail Farfel, Ph.D., as Chief Executive Officer - Continued progress toward i
ProMIS Neurosciences Announces Third Quarter 2022 Financial Results and Recent Highlights US$7.4 million private placement Gail Farfel, Ph.D., as Chief Executive Officer progress toward investigational new drug (IND) submission for PMN310 in Alzheimer's disease Ontario and C
Read more →PMNProMIS Neurosciences Announces Closing of US $7.4 Million Private Placement Toronto, Ontario and Cambridge, MA
ProMIS Neurosciences Announces Closing of US $7.4 Million Private Placement Toronto, Ontario and Cambridge, MA - October 12, 2022 - ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics ta
Read more →PMNProMIS Neurosciences appoints accomplished biopharmaceutical leader, Dr. Gail M. Farfel, as Chief Executive Officer New CEO brings 25 years' experience and successful track record in neurological and neuropsychiatric dru
Neurosciences appoints accomplished biopharmaceutical leader, Dr. Gail M. Farfel, as Chief Executive Officer CEO brings 25 years' experience and successful track record in neurological and neuropsychiatric drug development Ontario and CAMBRIDGE, Massachusetts - September 13, 20
Read more →PMNProMIS Neurosciences Announces Second Quarter 2022 Financial and Operating Results
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Aug. 15, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (Nasdaq: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins
Read more →PMNProMIS Neurosciences Announces Second Quarter
ProMIS Neurosciences Announces Second Quarter 2022 Financial and Operating Results Ontario and CAMBRIDGE, Massachusetts - August 15, 2022 - ProMIS Neurosciences, Inc. (TSX: PMN) (Nasdaq: PMN) ("ProMIS" or the "Company"), a biotechnology company focused on the discovery and dev
Read more →PMN▼ -5.4%on this news
ProMIS Neurosciences Presents at 2022 Alzheimer’s Association International Conference
TORONTO, Ontario and CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated i
Read more →PMNProMIS Neurosciences to Present at 2022 Alzheimer’s Association International Conference
TORONTO, Ontario and CAMBRIDGE, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated
Read more →PMNProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol "PMN" TORONTO, Ontario and CAMBRIDGE, Massachusetts - July 8 th , 2022 - ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN) ("ProMIS" or the "Company"),
ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol "PMN" TORONTO, Ontario and CAMBRIDGE, Massachusetts - July 8th, 2022 - ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN) ("ProMIS" or the "Company"), a biotechnology company focused on the discovery and deve
Read more →PMNPROMIS ANNOUNCES REVERSE SHARE SPLIT TO MEET NASDAQ LISTING CRITERIA
TORONTO, Ontario and CAMBRIDGE, MA, June 27, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of potential therapeutics targeting misfolded proteins such as toxic oligomers implicated in
Read more →PMNProMIS Neurosciences Announces Debt Amendment and Conversion
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins
Read more →PMNProMIS Neurosciences Announces Filing of Form 10 Registration Statement and Nasdaq Listing Application
TORONTO, Ontario and CAMBRIDGE, Massachusetts , June 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded protein
Read more →PMNProMIS Neurosciences Announces Authorization of Series 1 Preferred Shares
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins
Read more →PMNProMIS Neurosciences presents at the 2022 Neuro4D International Conference
TORONTO, Ontario and CAMBRIDGE, MA, May 17, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the devel
Read more →PMNProMIS Holds Annual and Special Meeting of Shareholders All Resolutions Approved
TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 13, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Corporation”), is pleased to announce the Annual and Special Meeting of Shareholders (the “Meeting”) of ProMIS was held online by
Read more →PMNProMIS Neurosciences Announces First Quarter 2022 Results
TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 13, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins
Read more →PMNProMIS Neurosciences Reports New Milestones in Potential Therapeutic Approaches for Amyotrophic Lateral Sclerosis (ALS)
TORONTO, Ontario and CAMBRIDGE, MA, April 28, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of potential therapeutics targeting misfolded proteins such as toxic oligomers implicated
Read more →PMNProMIS appoints experienced industry veteran Larry Altstiel as Chief Medical Officer
TORONTO, Ontario and CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicate
Read more →PMNProMIS Files Management Information Circular in Connection with Annual General and Special Meeting of Shareholders
TORONTO, Ontario and CAMBRIDGE, Massachusetts, April 07, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Corporation”), is pleased to announce it has mailed the Notice of Notice-and-Access (the “N&A Notice”) to shareholders of record
Read more →PMNProMIS Neurosciences Presents at the 2022 American Academy of Neurology Annual Meeting
TORONTO, Ontario and CAMBRIDGE, MA, April 07, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the dev
Read more →PMNProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development Summit
TORONTO, Ontario and CAMBRIDGE, MA , March 24, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the de
Read more →PMNProMIS Neurosciences Presents Preclinical Results of its Experimental Alzheimer’s Vaccine at the 2022 International AD/PDTM Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
TORONTO, Ontario and CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the
Read more →PMNProMIS Neurosciences Announces Fiscal Year 2021 Results
TORONTO, Ontario and CAMBRIDGE, Massachusetts , March 17, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded prote
Read more →PMNProMIS Neurosciences to Present at the 2022 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PDTM) and Related Neurological Disorders
TORONTO, Ontario and CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the
Read more →PMNProMIS Neurosciences’ PMN310 antibody demonstrates significant cognitive benefit in a mouse model of Alzheimer’s disease
TORONTO, Ontario and CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, announce
Read more →PMNProMIS Neurosciences Appoints Renowned Neuroscientists, Dr. Guy Rouleau and Dr. Alain Dagher to its Scientific Advisory Board
TORONTO, Ontario and CAMBRIDGE, Mass. , Feb. 03, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicate
Read more →PMNProMIS Neurosciences Appoints Internationally Recognized Neuroscientist Dr. Cheryl Wellington to its Scientific Advisory Board
TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated
Read more →PMNProMIS Neurosciences Announces Antibody Program for Schizophrenia Therapy and Recruitment of Dr. Carsten Korth to its Scientific Advisory Board
TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated
Read more →PMNProMIS Neurosciences to Participate in the Biotech Showcase 2022 Virtual Panel Discussion: Aduhelm Stimulating the Next Generation of Alzheimer’s Treatment
TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated
Read more →PMNProMIS Neurosciences to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference
TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated
Read more →PMNProMIS Neurosciences Issues Chairman’s Memorandum
TORONTO, Ontario and CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neur
Read more →PMNProMIS Neurosciences Shareholders Approve Special Resolution
TORONTO and CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development o
Read more →PMNProMIS Neurosciences Announces Third Quarter 2021 Results
TORONTO and CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the de
Read more →PMNProMIS Neurosciences Announces Update to Senior Management Team
TORONTO and CAMBRIDGE, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of
Read more →PMNProMIS Neurosciences Appoints Accomplished Biotech Executive, Dr. Maggie Shafmaster, to its Board of Directors
TORONTO and CAMBRIDGE, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of
Read more →PMNProMIS Neurosciences Files Special Meeting Proxy Material
For any questions, please contact ProMIS’ proxy solicitation agent, Laurel Hill Advisory Group at 1-877-452-7184 (+1-416-304-0211 outside North America) or email assistance@laurelhill.com. TORONTO and CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc.
Read more →PMNProMIS Neurosciences Announces Special Shareholder Meeting
TORONTO and CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development o
Read more →PMNProMIS Neurosciences to Present at the Second Annual Undruggable Leaders Forum, September 15-16, 2021
TORONTO and CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegener
Read more →PMNProMIS Neurosciences to Participate in H.C. Wainwright & Co. 23rd Annual Investment Conference
TORONTO and CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegener
Read more →PMNProMIS Neurosciences appoints accomplished biotechnology executive, Josh Mandel-Brehm, to its Board of Directors
TORONTO and CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of
Read more →PMNProMIS Neurosciences Closes Upsized US$20,125,000 Public Offering
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO and CAMBRIDGE, Mass., Aug. 25, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (the “Company” or “ProMIS”), a biotechnology company focused on the discovery and development
Read more →PMNProMIS Neurosciences Inc. Announces Pricing of US$15 Million Public Offering of Units
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 18, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (“ProMIS” or the “Company”) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therape
Read more →PMNProMIS Neurosciences Inc. Announces Upsize of Previously Announced Public Offering of Units to US$17.5M
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 18, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (“ProMIS” or the “Company”) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therape
Read more →PMNProMIS Neurosciences Inc. Announces US$15 Million Offering of Units
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (“ProMIS” or the “Company”) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeu
Read more →PMNProMIS Neurosciences Announces Second Quarter 2021 Results
TORONTO and CAMBRIDGE, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the de
Read more →PMNProMIS Neurosciences to Present at 2021 Alzheimer’s Association International Conference
TORONTO and CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences Obtains Receipt for Final Base Shelf Prospectus
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES TORONTO and CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:
Read more →PMNProMIS Neurosciences Announces Results of Annual Meeting of Shareholders
TORONTO and CAMBRIDGE, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences congratulates Biogen on FDA accelerated approval of aducanumab for Alzheimer’s disease
TORONTO and CAMBRIDGE, Mass., June 08, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences Files Preliminary Short Form Base Shelf Prospectus
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES TORONTO and CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: P
Read more →PMNProMIS Neurosciences appoints renowned scientist, Dr. David Wishart as Chief Physics Officer
TORONTO, and CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences initiates commercialization of COVID-19 serology assay
TORONTO and CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of n
Read more →PMNProMIS Neurosciences re-initiates path to IND for PMN310 with producer cell line development
TORONTO and CAMBRIDGE, Mass., May 21, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of n
Read more →PMNProMIS Neurosciences appoints accomplished biotechnology executive, Neil Warma, to its Board of Directors
TORONTO and CAMBRIDGE, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of n
Read more →PMNProMIS Neurosciences Announces First Quarter 2021 Results
TORONTO and CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the dev
Read more →PMNProMIS Neurosciences appoints renowned neuroscientist, Dr. Rudolph Tanzi, as Chair of Scientific Advisory Board
TORONTO and CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of n
Read more →PMNProMIS Neurosciences Announces Fiscal Year 2020 Results
TORONTO and CAMBRIDGE, Mass., March 31, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the d
Read more →PMNProMIS Neurosciences Completes US$7M (CDN$8.75M) Financing with Distinguished Group of Boston Based Investors
TORONTO and CAMBRIDGE, Mass., March 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences Offers Perspectives on Recent Progress in the Alzheimer’s/Amyloid Field
Two positive events in January support PMN310 “best in class” positioning TORONTO and CAMBRIDGE, Mass., Feb. 02, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeuti
Read more →PMNProMIS Neurosciences Announces Strategic Priorities for 2021
TORONTO and CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences Completes Offering of Special Warrants
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES TORONTO and CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PM
Read more →PMNProMIS Neurosciences Announces Third Quarter 2020 Results
TORONTO and CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the de
Read more →PMNProMIS Neurosciences offers comments on recent FDA Advisory Committee meeting on aducanumab for the treatment of Alzheimer’s disease
TORONTO and CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences Closes First Tranche of Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES TORONTO and CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: P
Read more →PMNProMIS Neurosciences’ Dr. Neil Cashman CSO, to Speak at 2020 ALS ONE Research Symposium
TORONTO and CAMBRIDGE, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences adds Dr. David Wishart to its Scientific Advisory Board
TORONTO and CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences Announces Up to $3 Million Private Placement Offering of Special Warrants
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES TORONTO and CAMBRIDGE, Mass., Oct. 23, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PM
Read more →PMNProMIS Neurosciences Offers its Perspective on the Likelihood of Regulatory Approval of Aducanumab
TORONTO and CAMBRIDGE, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences’ Neil Cashman to Speak at Protein Misfolding Drug Discovery Conference
ProMIS’ proprietary drug discovery and development platform highlighted for ability to create novel antibodies, diagnostics and vaccine candidates for neurodegenerative diseases TORONTO and CAMBRIDGE, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN)
Read more →PMNProMIS Neurosciences to develop multivalent vaccine for Alzheimer’s disease
TORONTO and CAMBRIDGE, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegener
Read more →PMNProMIS Neurosciences to Participate in H.C. Wainwright & Co. 22nd Annual Investment Conference
TORONTO and CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegener
Read more →PMNProMIS Neurosciences Announces Second Quarter 2020 Results
TORONTO and CAMBRIDGE, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the de
Read more →PMNProMIS Neurosciences and BC Neuroimmunology announce revenue-sharing joint venture agreement to develop and offer blood-based diagnostic tests for Alzheimer’s disease
TORONTO and CAMBRIDGE, Mass., July 09, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique, core technology to predict novel targets (peptide antigens) on the molecular surface of complex, misfolded proteins, and BC Neuroimmunology
Read more →PMNProMIS Neurosciences announces adjournment and change of location of annual meeting of shareholders
TORONTO and CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences and collaborator BC Neuroimmunology announce significant progress on development of highly accurate antibody test for COVID-19
TORONTO and CAMBRIDGE, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique, core technology to predict novel targets on the molecular surface of complex proteins, and its collaborator BC Neuroimmunology Lab Inc. (BC
Read more →PMNProMIS Neurosciences and collaborative team receive Supercluster Award supporting avoidance of future pandemics by new strains of the COVID-19 virus
TORONTO and CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique core technology to predict novel targets on the molecular surface of complex proteins, together with a team of commercial and academic collab
Read more →PMNProMIS Neurosciences Chairman’s Update details new programs from expanded use of novel technology platform
TORONTO and CAMBRIDGE, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerat
Read more →PMNProMIS Neurosciences and BC Neuroimmunology expand collaboration to develop and commercialize proprietary diagnostic assays
TORONTO and CAMBRIDGE, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique, core technology to predict novel targets on the molecular surface of complex proteins, announced today that, in addition to its ongoing prog
Read more →PMNProMIS Neurosciences Announces First Quarter 2020 Results
TORONTO and CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the dev
Read more →PMNProMIS Neurosciences identifies multiple novel targets on SARS CoV-2 for development of a highly accurate COVID-19 antibody test
TORONTO, Ontario and CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique, core technology to predict novel targets on the molecular surface of complex proteins, has advanced its program to develop a high-t
Read more →PMNProMIS Neurosciences develops novel antagonists for RACK1, a protein involved in numerous neurodegenerative diseases, including ALS
TORONTO and CAMBRIDGE, Mass., May 06, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerat
Read more →PMNProMIS Neurosciences creates novel intrabodies for ALS, frontotemporal dementia and other neurodegenerative diseases
TORONTO and CAMBRIDGE, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegener
Read more →PMNProMIS Neurosciences commends Biogen for clarifying aducanumab regulatory filing
Ongoing rolling BLA submission to the FDA supports completion by Q3; ProMIS applauds advancement in profoundly challenging environment TORONTO and CAMBRIDGE, Mass., April 22, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company f
Read more →PMNProMIS Neurosciences announces collaboration to develop serological test to assess COVID-19 immunity
TORONTO and CAMBRIDGE, Mass., April 15, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with a unique, core technology to predict novel targets on the molecular surface of complex proteins, announced today a collaboration with Dr. Hans Fry
Read more →PMNProMIS Neurosciences to Present Data and Moderate Session at AAIC 2020
TORONTO and CAMBRIDGE, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegener
Read more →PMNPROMIS NEUROSCIENCES ANNOUNCES APPROVAL FOR WARRANT REPRICING
/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, March 24, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (“ProMIS” or the “Company”) (TSX: PMN) (OTCQB: ARFXF) announces that the Company has received approval from the Toronto
Read more →PMNProMIS Neurosciences Announces Fiscal Year 2019 Annual Results
TORONTO and CAMBRIDGE, Mass., March 18, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the d
Read more →PMNProMIS Neurosciences Initiates Natural History Study of Blood-Based Biomarkers in Alzheimer’s Disease
TORONTO and CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), with Toronto Memory Program, Canada’s largest and most experienced memory clinic and site for drug treatment trials in Alzheimer’s disease (AD) has initiated a pi
Read more →PMNProMIS Neurosciences Announces Gross Proceeds of $1,257,970 Related to the Exercise of Common Stock Warrants
TORONTO and CAMBRIDGE, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences to Participate in Noble Capital Markets 16th Annual Investor Conference
TORONTO and CAMBRIDGE, Mass, Feb. 11, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerat
Read more →PMNProMIS Neurosciences to Participate in the BIO CEO & Investor Conference
TORONTO and CAMBRIDGE, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences Data for Alzheimer’s Disease Program Targeting Tau Accepted for Presentation at Tau2020
TORONTO and CAMBRIDGE, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences to present at Sachs 3rd Annual Neuroscience Innovation Forum
TORONTO and CAMBRIDGE, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences issues Chairman’s Update detailing positive outlook for Alzheimer’s disease therapy, pipeline in 2020
TORONTO and CAMBRIDGE, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences Completes Second Closing of Private Placement
NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Dec. 31, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (“ProMIS” or the “Company”) (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of
Read more →PMNProMIS Neurosciences’ Alzheimer’s disease program takes on renewed significance following positive aducanumab news
TORONTO and CAMBRIDGE, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences Completes First Closing of Private Placement
NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targ
Read more →PMNProMIS Neurosciences Announces Third Quarter 2019 Results
TORONTO and CAMBRIDGE, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences Undertaking $6.5M Private Placement
TORONTO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (“ProMIS” or the “Company”) (TSX: PMN; OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodeg
Read more →PMNProMIS Neurosciences Outlines Best-in-class Approach to Amyloid-beta-targeting Drug Candidates for Alzheimer’s Disease
TORONTO and CAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43
TORONTO and CAMBRIDGE, Mass., Oct. 23, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences advances Alzheimer’s disease program targeting neurotoxic forms of tau
TORONTO and CAMBRIDGE, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences Identifies Novel Antibody Candidates for Multiple System Atrophy
TORONTO and CAMBRIDGE, Mass., Oct. 08, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences Executive Chairman Eugene Williams to Speak on Panel at Fall Investor Summit
TORONTO and CAMBRIDGE, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegener
Read more →PMNProMIS Neurosciences to Present at H.C. Wainwright Investor Conference
TORONTO and CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegener
Read more →PMNProMIS Neurosciences Appoints Internationally Recognized Researcher in Alzheimer’s Disease in Down Syndrome Dr. Andre Strydom to its Scientific Advisory Board
TORONTO and CAMBRIDGE, Mass., Aug. 27, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences Announces Second Quarter 2019 Results
TORONTO and CAMBRIDGE, Mass., Aug. 13, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences Highlights Data for PMN310 at AAIC 2019
TORONTO and CAMBRIDGE, Mass., July 18, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences to Present Data at 2019 Alzheimer’s Association International Conference
TORONTO and CAMBRIDGE, Mass., July 10, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences’ Data for Alzheimer’s Disease Clinical Candidate PMN310 Published in Scientific Reports
TORONTO and CAMBRIDGE, Mass., July 09, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences’ PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies
TORONTO, Ontario and CAMBRIDGE, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neur
Read more →PMNProMIS Neurosciences Closing Private Placement
NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, June 26, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targe
Read more →PMNProMIS Neurosciences Appoints Renowned Parkinson’s Disease Expert Dr. C. Warren Olanow to Scientific Advisory Board
TORONTO and CAMBRIDGE, Mass., June 19, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences Presents Lead Program for Alzheimer’s Disease at Prestigious Keystone Symposia Scientific Conference
TORONTO and CAMBRIDGE, Mass., June 05, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences’ Eugene Williams to Present at JLABS’ Conference on Innovations in Neurodegenerative Diseases
TORONTO and CAMBRIDGE, Mass., May 29, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerat
Read more →PMNProMIS Neurosciences Identifies Novel Antibodies for Alzheimer’s Disease with Selectivity for the Neurotoxic Form of Tau
TORONTO and CAMBRIDGE, Mass., May 28, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerat
Read more →PMNProMIS Neurosciences Announces First Quarter 2019 Results
TORONTO and CAMBRIDGE, Mass., May 14, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerat
Read more →PMNProMIS Neurosciences to Participate in the Think Equity Investor Conference
TORONTO and CAMBRIDGE, Mass., April 23, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of
Read more →PMNProMIS Neurosciences to Participate in Microcap Spring Investor Summit 2019
TORONTO and CAMBRIDGE, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of
Read more →PMNProMIS Neurosciences to Present Data for Potential Best-in-Class Antibody Candidates for Parkinson’s Disease at AD/PD™ 2019 Conference
TORONTO and CAMBRIDGE, Mass., March 19, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegener
Read more →PMNProMIS Neurosciences Announces Fiscal Year 2018 Annual Results
TORONTO and CAMBRIDGE, Mass., March 15, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegener
Read more →PMNProMIS Neurosciences Adds Pharmaceutical Leader Timothy Rothwell to Board of Advisors
TORONTO, Ontario and CAMBRIDGE, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neur
Read more →PMNProMIS Neurosciences Completes Private Placement of Units
NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Jan. 23, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (“ProMIS” or the “Company”) (TSX: PMN); (OTCQB:ARFXF) is pleased to announce that it has closed a private placement of 9,56
Read more →PMNProMIS Neurosciences to Participate in NobleCon15 and CanTech Investment Conferences
TORONTO and CAMBRIDGE, Mass., Jan. 17, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of n
Read more →PMNProMIS Neurosciences to Present at Sachs Associates Neuroscience Innovation Forum and China Focus@JPMWeek
TORONTO and CAMBRIDGE, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences Appoints Renowned Neuroscientist, Dr. Rudolph Tanzi, to Scientific Advisory Board
TORONTO and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of
Read more →PMNProMIS Neurosciences Issues Year-to-Date Update, Highlighting 2018 Accomplishments
TORONTO and CAMBRIDGE, Mass., Nov. 20, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegener
Read more →PMNProMIS Neurosciences Announces Third Quarter 2018 Results
TORONTO and CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegener
Read more →PMNProMIS Neurosciences Discusses Critical Importance of Selectively Targeting the Root Cause of Alzheimer’s Disease
Narrated white paper reveals lessons learned from 15 years of drug development; pressing need to selectively target the toxic oligomer TORONTO and CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company fo
Read more →PMNProMIS Neurosciences Identifies Novel Targets on Tau Protein Involved in the Development of Alzheimer’s Disease and Other Dementias
ProMIS’ proprietary discovery platform generates additional potential opportunities for pharma partnering TORONTO and CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and de
Read more →PMNProMIS Neurosciences Identifies Novel Antibody Drug Candidates for Parkinson’s Disease
TORONTO and CAMBRIDGE, Mass., Oct. 11, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenera
Read more →PMNProMIS Neurosciences Appoints James Kupiec, MD as Chief Medical Officer
TORONTO and CAMBRIDGE, Mass., Sept. 13, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN; OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of n
Read more →PMNProMIS Neurosciences to Present at Upcoming Investor Conferences
TORONTO and CAMBRIDGE, Mass., Jan. 25, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that it will participate in two upcoming industry c
Read more →PMNProMIS Neurosciences Issues White Paper Entitled: “Not All Amyloid Beta Therapeutics Are Created Equal”
ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease Shows Improved Therapeutic Potency versus other Amyloid Beta-Directed Antibodies TORONTO and CAMBRIDGE, Mass., Jan. 25, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a biotechnology company focused on th
Read more →PMNProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease Shows Potential for Improved Therapeutic Potency versus Other Amyloid Beta-Directed Antibodies
TORONTO and CAMBRIDGE, Mass., Jan. 23, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced further results of its prev
Read more →PMNProMIS Neurosciences Issues Response to Recent Market Activity
TORONTO and CAMBRIDGE, Mass., Jan. 22, 2018 (GLOBE NEWSWIRE) -- At the request of IIROC ("Investment Industry Regulatory Organization of Canada"), ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF) (the "Company") wishes to confirm that it is not aware of any material, undisclose
Read more →PMNProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies
TORONTO and CAMBRIDGE, Mass., Jan. 04, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that its lead product candidate for Alzheimer’s dis
Read more →PMNProMIS Neurosciences Announces Trading on OTCQB Venture Market
TORONTO and CAMBRIDGE, Mass., Dec. 04, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that its common shares have been approved for trading on the OTCQ
Read more →PMNProMIS Neurosciences Announces Third Quarter 2017 Results
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Nov. 13, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced its operational and financial results for the th
Read more →PMNProMIS Neurosciences Lead Product Candidate, PMN310, Shows Desired Target Binding Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies for Alzheimer’s Disease
TORONTO and CAMBRIDGE, Mass., Oct. 17, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that its lead product candidate for Alzheimer’s dis
Read more →PMNProMIS Neurosciences Provides Third Quarter Update for 2017
TORONTO and CAMBRIDGE, Mass., Oct. 11, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today provided a corporate update for the third quarter of 2017, in
Read more →PMNProMIS Neurosciences Chief Scientific Officer, Dr. Neil Cashman, to Present at Third Annual R&D Technologies Conference
Presentation highlights the use of ProMIS’ proprietary discovery platform to identify novel therapeutic targets on misfolded proteins in multiple neurodegenerative diseases TORONTO and CAMBRIDGE, Mass., Sept. 28, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a biotechnolo
Read more →PMNProMIS Neurosciences Independent Director Anthony J. Giovinazzo Recognized with Inaugural Bloom Burton Award for Innovation in Canadian Healthcare
TORONTO, ONTARIO and CAMBRIDGE, MA , Sept. 21, 2017 (GLOBE NEWSWIRE) -- ERN UK
Read more →PMNProMIS Neurosciences Announces Successful Humanization of Lead Product Candidate PMN310 for Alzheimer’s Disease
TORONTO and CAMBRIDGE, Mass., Sept. 19, 2017 (GLOBE NEWSWIRE) -- ERN UK
Read more →PMNProMIS Neurosciences Designates PMN330 as Third, Validated Lead Product for Development in Alzheimer’s Disease
TORONTO and CAMBRIDGE, Mass., Sept. 13, 2017 (GLOBE NEWSWIRE) -- ERN UK
Read more →PMNProMIS Neurosciences Announces Second Quarter 2017 Results
TORONTO and CAMBRIDGE, Mass., Aug. 11, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (“ProMIS” or the “Company”), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced its operational and financial results
Read more →Competitive Position
How PMN ranks across every disease it competes inCompetitive Position is a premium feature
See how PMN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial